Anti-RET Antibody, clone 2K12 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 2K12 is a ZooMAb^® Rabbit recombinant monoclonal antibody that specifically detects RET. It targets an epitope within 18 amino acids from the cytoplasmic domain in the C-terminal half. Reacts with both isoforms.

KLH-conjugated linear peptide corresponding to 18 amino acids from the cytoplasmic domain in the C-terminal half of human Proto-oncogene tyrosine-protein kinase receptor Ret (RET).

Quality Control Testing

Evaluated by Western Blotting in Neuro2A cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected RET in Neuro2A cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected RET in SH-SY5Y and SK-N-SH cell lysates.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected RET in SH-SY5Y cells.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected RET in human colon tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Proto-oncogene tyrosine-protein kinase receptor Ret (UniProt: P07949; also known as EC: 2.7.10.1, Cadherin family member 12, Proto-oncogene c-Ret) is encoded by the RET (also known as CDHF12, CDHR16, PTC, RET51) gene (Gene ID: 5979) in human. RET is a single-pass type I membrane protein that is synthesized with a signal peptide (aa 1-28), which is subsequently cleaved off to produce the mature protein that contains an extracellular domain (aa 29-635), a transmembrane domain (aa 636-657), and a cytoplasmic domain (aa 658-1114). RET is a receptor tyrosine-protein kinase that is involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation. It is also involved in orchestration intestine organogenesis, development of enteric nervous system, and renal organogenesis during embryonic life. It also promotes the formation of Peyer′s patch-like structures, a major component of the gut-associated lymphoid tissue. RET is shown to be active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. In the presence of the ligand GDNF in somatotrophs, it promotes survival and down regulates growth hormone production. However, in the absence of GDNF, it triggers apoptosis. Its protein kinase domain is localized in amino acids 724-1016. RET is auto-phosphorylated on C-terminal tyrosine residues upon ligand stimulation. The phosphorylated form is known to interact with phospholipase 1, and growth factor receptor bound protein 7 (Grb7). It undergoes dephosphorylation on tyrosine residues 905, 1015, and 1062 by protein tyrosine phosphatase receptor type J (PTPRJ). Mutations in RET gene have been linked to multiple types of cancers, including colorectal cancer, medullary thyroid carcinoma, and pheochromocytoma. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Mulligan, LM. (2019). Front. Physiol. 9; 1873; Kawamoto, Y., et al. (2004). J. Biol. Chem. 279(14); 14213-14224; Salvatore, D., et al. (2000). J. Clin. Endocrinol. Metab. 85(10); 3898-3907).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.